Innovent Starts US Trial of CD47/PD-L1 Bispecific Antibody

Innovent Bio of Suzhou started a US Phase I trial of its anti-CD47/PD-L1 bispecific antibody as a second-line therapy for patients with advanced malignancies. According to Innovent, IBI322 binds to tumor cells more selectively than anti-CD47 monoclonal antibodies, reducing the possibility of binding to CD47 on red blood cells. This feature could reduce the toxicity associated with anti-CD47 antibodies and offer greater antitumor activity. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //